Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AS-403
- Development stage
- Preclinical
- Lead developer
- Amyloid Solution
- Modality
- Small Molecules
01
Overview
AS-403 is a small molecule drug candidate currently in the lead optimization stage of preclinical development for the treatment of Alzheimer's disease. Developed by Amyloid Solution, it is part of the company's GLIA program, which focuses on modulating glial cell activity to address neurodegeneration and neuroinflammation. While the specific biological target of AS-403 remains non-disclosed, the program aims to provide therapeutic benefits by targeting glial-mediated pathways involved in the progression of Alzheimer's disease.
Beyond the preview
Go deeper on AS-403.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AS-403.